158 related articles for article (PubMed ID: 14996719)
1. Hypermethylation of a small CpGuanine-rich region correlates with loss of activator protein-2alpha expression during progression of breast cancer.
Douglas DB; Akiyama Y; Carraway H; Belinsky SA; Esteller M; Gabrielson E; Weitzman S; Williams T; Herman JG; Baylin SB
Cancer Res; 2004 Mar; 64(5):1611-20. PubMed ID: 14996719
[TBL] [Abstract][Full Text] [Related]
2. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
3. Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer.
Moelans CB; Verschuur-Maes AH; van Diest PJ
J Pathol; 2011 Oct; 225(2):222-31. PubMed ID: 21710692
[TBL] [Abstract][Full Text] [Related]
4. Synergistic silencing by promoter methylation and reduced AP-2α transactivation of the proapoptotic HRK gene confers apoptosis resistance and enhanced tumor growth.
Xu M; Chen X; Chen N; Nie L; Li X; Li Q; Zeng H; Zhou Q
Am J Pathol; 2013 Jan; 182(1):84-95. PubMed ID: 23159945
[TBL] [Abstract][Full Text] [Related]
5. Promoter CpG island hypermethylation during breast cancer progression.
Park SY; Kwon HJ; Lee HE; Ryu HS; Kim SW; Kim JH; Kim IA; Jung N; Cho NY; Kang GH
Virchows Arch; 2011 Jan; 458(1):73-84. PubMed ID: 21120523
[TBL] [Abstract][Full Text] [Related]
6. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients.
Honorio S; Agathanggelou A; Schuermann M; Pankow W; Viacava P; Maher ER; Latif F
Oncogene; 2003 Jan; 22(1):147-50. PubMed ID: 12527916
[TBL] [Abstract][Full Text] [Related]
7. Differential distribution of DNA methylation within the RASSF1A CpG island in breast cancer.
Yan PS; Shi H; Rahmatpanah F; Hsiau TH; Hsiau AH; Leu YW; Liu JC; Huang TH
Cancer Res; 2003 Oct; 63(19):6178-86. PubMed ID: 14559801
[TBL] [Abstract][Full Text] [Related]
8. Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation.
Evron E; Umbricht CB; Korz D; Raman V; Loeb DM; Niranjan B; Buluwela L; Weitzman SA; Marks J; Sukumar S
Cancer Res; 2001 Mar; 61(6):2782-7. PubMed ID: 11289162
[TBL] [Abstract][Full Text] [Related]
9. RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression.
Subramaniam MM; Chan JY; Soong R; Ito K; Ito Y; Yeoh KG; Salto-Tellez M; Putti TC
Breast Cancer Res Treat; 2009 Jan; 113(1):113-21. PubMed ID: 18256927
[TBL] [Abstract][Full Text] [Related]
10. Methylation in the p53 promoter is a supplementary route to breast carcinogenesis: correlation between CpG methylation in the p53 promoter and the mutation of the p53 gene in the progression from ductal carcinoma in situ to invasive ductal carcinoma.
Kang JH; Kim SJ; Noh DY; Park IA; Choe KJ; Yoo OJ; Kang HS
Lab Invest; 2001 Apr; 81(4):573-9. PubMed ID: 11304577
[TBL] [Abstract][Full Text] [Related]
11. Regulation of KiSS-1 metastasis suppressor gene expression in breast cancer cells by direct interaction of transcription factors activator protein-2alpha and specificity protein-1.
Mitchell DC; Abdelrahim M; Weng J; Stafford LJ; Safe S; Bar-Eli M; Liu M
J Biol Chem; 2006 Jan; 281(1):51-8. PubMed ID: 16260418
[TBL] [Abstract][Full Text] [Related]
12. GSTP1 promoter hypermethylation is an early event in breast carcinogenesis.
Lee JS
Virchows Arch; 2007 Jun; 450(6):637-42. PubMed ID: 17479284
[TBL] [Abstract][Full Text] [Related]
13. Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer.
Nass SJ; Herman JG; Gabrielson E; Iversen PW; Parl FF; Davidson NE; Graff JR
Cancer Res; 2000 Aug; 60(16):4346-8. PubMed ID: 10969774
[TBL] [Abstract][Full Text] [Related]
14. CpG island promoter methylation and silencing of 14-3-3sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2.
Pulukuri SM; Rao JS
Oncogene; 2006 Aug; 25(33):4559-72. PubMed ID: 16786000
[TBL] [Abstract][Full Text] [Related]
15. Detection of Slit2 promoter hypermethylation in tissue and serum samples from breast cancer patients.
Kim GE; Lee KH; Choi YD; Lee JS; Lee JH; Nam JH; Choi C; Park MH; Yoon JH
Virchows Arch; 2011 Oct; 459(4):383-90. PubMed ID: 21894562
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous CXCL12 and ESR1 CpG island hypermethylation correlates with poor prognosis in sporadic breast cancer.
Ramos EA; Camargo AA; Braun K; Slowik R; Cavalli IJ; Ribeiro EM; Pedrosa Fde O; de Souza EM; Costa FF; Klassen G
BMC Cancer; 2010 Jan; 10():23. PubMed ID: 20109227
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene.
Cheng CW; Wu PE; Yu JC; Huang CS; Yue CT; Wu CW; Shen CY
Oncogene; 2001 Jun; 20(29):3814-23. PubMed ID: 11439345
[TBL] [Abstract][Full Text] [Related]
18. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.
Potapova A; Hoffman AM; Godwin AK; Al-Saleem T; Cairns P
Cancer Res; 2008 Feb; 68(4):998-1002. PubMed ID: 18281473
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers.
Sidiropoulos M; Pampalakis G; Sotiropoulou G; Katsaros D; Diamandis EP
Tumour Biol; 2005; 26(6):324-36. PubMed ID: 16254462
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of helicase-like transcription factor by promoter hypermethylation in human gastric cancer.
Leung WK; Yu J; Bai AH; Chan MW; Chan KK; To KF; Chan FK; Ng EK; Chung SC; Sung JJ
Mol Carcinog; 2003 Jun; 37(2):91-7. PubMed ID: 12766908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
